Trial · NCT05355337
Pramipexole for Anhedonic Depression
NCT05355337, Phase 3, Completed, Region Skane
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Pramipexole for Anhedonic Depression. Trials, record NCT05355337. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05355337
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pramipexole for Anhedonic Depression
- NCT number
- NCT05355337
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 85 participants, actual
- Lead sponsor
- Region Skane
- Conditions
- Psychiatric Disorders Mood, Anhedonia, Depression
- Interventions
- Pramipexole, Placebo
- First posted
- 2022-05-02
- Last updated
- 2026-04-28
- Other registries' IDs
- eudract:2022-001563-26
Source ClinicalTrials.gov
Registered outcomes45
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effect on anhedonia symptoms | 9 weeks | Change in Snaith-Hamilton Pleasure Scale (SHAPS) self-report total score from baseline to week 9. Higher scores equal more severe anhedonoa. Score range 14-56 |
| Secondary | Effect on core depression symptoms | 9 weeks | Change in Hamilton Rating Scale for Depression 6 items (HDRS-6) total score baseline to week 9 |
| Secondary | Effect on other anhedonic domains not measured by SHAPS | 9 weeks | Change in Dimensional Anhedonia Rating Scale (DARS) total score (inverse scale, lower points equals more anhedonia) from baseline to week 9 |
| Secondary | Effect on general depressive symptoms | 9 weeks | Change in Montgomery-Åsberg Depression Rating Scale (MADRS-S) total score from baseline to week 9 |
| Secondary | Effect on sleep disturbances | 9 weeks | Change in Insomnia Severity Index (ISI) total score from baseline to week 9 |
| Secondary | Effect on apathy symptoms | 9 weeks | Change in Apathy Evaluation Scale (AES) total score from baseline to week 9 |
| Secondary | Effect on anxiety symptoms | 9 weeks | Change in Generalized Anxiety Disorder 7-item scale (GAD-7) total score from baseline to week 9 |
| Secondary | Effect on quality of life | 9 weeks | Change in Brunnsviken Brief Quality of life scale (BBQ) total score from baseline to week 9 |
| Secondary | Effect on number of steps | 9 weeks | Change in parameter "number of steps" measured with a digital activity monitor (accelerometry bracelet), from baseline to week 9 |
| Secondary | Effect on distance travelled | 9 weeks | Change in parameter "distance travelled" measured with a digital activity monitor (accelerometry bracelet), from baseline to week 9 |
1 to 10 of 45Source ClinicalTrials.gov
See all 45 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Monetary Incentive Delay | Secondary outcome |
Source ConductCognition
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05355337
GET https://conductscience.org/api/trials/v1/NCT05355337/registered?page=2